MedTrace Logo

Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors

NCT00148993 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2011-04-08

No results posted yet for this study

Summary

The goal of this study is to apply allogeneic tumor cell vaccination for immunotherapy in patients with micro-metastatic disease and/or in patients at high risk disease progression. The present study will use allogeneic tumor cell lines for tumor cell vaccines that share MHC determinants with the patient aiming to overcome possible restriction of antigen presentation.

Conditions

  • Metastatic Solid Tumors

Interventions

BIOLOGICAL

Tumor Cell Vaccine

Sponsors & Collaborators

  • The International Center for Cell Therapy & Cancer Immunotherapy (CTCI)

    collaborator UNKNOWN

  • Hadassah Medical Organization

    lead OTHER

Principal Investigators

  • shimon slavin, MD · The International Center for Cell Therapy & Cancer Immunotherapy (CTCI)

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-07-31
Completion
2005-07-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00148993 on ClinicalTrials.gov